EGFR 및 ALK의 억제 및 분해 유도 화합물

EGFR 및 ALK를 억제하거나 EGFR 및 ALK의 분해를 유도하는 일반식 (X)의 신규한 화합물, 및 상기 화합물을 함유하는 약제학적 조성물이 제공된다. 상기 화합물 및 약제학적 조성물은 EGFR 및 ALK 키나아제와 관련된 질병, 예를 들면, 암을 치료하는데 사용될 수 있다. 또한, 본 발명은 상기 화합물의 제조 방법 및 용도를 제공한다. JPEGpct00376.jpg7698.

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 26. Apr. Zur Gesamtaufnahme - year:2022

Sprache:

Koreanisch

Beteiligte Personen:

ZHAO YANPING [VerfasserIn]
WANG HONGJUN [VerfasserIn]
WANG YEMING [VerfasserIn]
FAN FUTIAN [VerfasserIn]
JIANG YUANYUAN [VerfasserIn]
WANG XIAOQIAN [VerfasserIn]
LIANG HUINING [VerfasserIn]
XIE YONG [VerfasserIn]
ZHANG YANHAO [VerfasserIn]
LIU KAI [VerfasserIn]
FENG ZEWANG [VerfasserIn]
LIU XUELIAN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

615
A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d)
A61P: Specific therapeutic activity of chemical compounds or medicinal preparations
C07D: Heterocyclic compounds (macromolecular compounds c08)
C07F: Acyclic, carbocyclic, or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium (metal-containing porphyrins c07d0487220000;macromolecular compounds c08)
Che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-04-26, Last update posted on www.tib.eu: 2022-11-24, Last updated: 2023-02-09

Patentnummer:

KR20220051244

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA016213920